When you try to access the page, a notification appears stating that “unusual actions” were performed on behalf of the account. Account-holders have asked followers to write to Twitter management asking them to unblock
The administration of the social network Twitter has decided to block the account of the Russian vaccine Sputnik V. This was reported by the Russian Direct Investment Fund (RDIF).
“We are investigating the reasons for what happened. We ask all our subscribers to write on Twitter with a request to restore access to us, “the message says.
The RDIF noted that the account published “open and transparent” information about the vaccine. In particular, it announced a proposal to AstraZeneca to create a combination vaccine against COVID-19. “Through Twitter, we offered AstraZeneca to use one of the Sputnik V components,” the RDIF said.
The Sputnik V vaccine page appeared on Twitter last August. During this time, 322 tweets were posted to the account. 22.7 thousand users are subscribed to the page. Now, when you try to access the Russian vaccine page, the following message is displayed: “You are seeing this warning because unusual actions were performed on behalf of this account.”
The Russian coronavirus vaccine Sputnik V was registered on August 11. The drug was developed at the N.N. N.F. Gamaliel of the Ministry of Health of Russia. The drug has passed three stages of clinical trials. The first foreign country to take part in trials of this vaccine was Belarus. Later, RDIF agreed to supply the drug to a number of countries. In the first week of December, the fund received preliminary bids for 1.2 billion doses of vaccine from more than 50 countries. It is expected that the vaccine for supply to foreign markets will be produced by RDIF’s international partners in India, Brazil, China, South Korea, and other countries.
At the end of November, the creators of Sputnik V proposed joint drug trials to AstraZeneca. “If they go to a new clinical trial, we suggest trying the combination regimen of AstraZeneca with Sputnik V to improve efficacy. Combined vaccines can become important for revaccination, “- noted the creators of the Russian drug.
AstraZeneca agreed to this proposal, and on December 11, the company began clinical trials of a combination of its own vaccine against coronavirus infection with the Russian drug Sputnik V. Research on different modes of vaccine use will help create more flexible vaccination schedules and provide doctors with a wider choice of approaches to prevent coronavirus, the company said. The combination of the British and Russian vaccines is expected to result in an enhanced immune response.